Support teaching, research, and patient care.
Dr. Enemchukwu received her undergraduate degree from Duke University. She subsequently earned her combined degree in Medicine (MD) and Public Health (MPH) at the University of North Carolina School of Medicine and Gillings School of Global Public Health. She completed her General Surgery and Urology training at Vanderbilt University Medical Center. She then went on to complete a prestigious fellowship in Female Pelvic Medicine & Reconstructive Surgery with concurrent training in Male Voiding Dysfunction and Neurourology at NYU Langone Medical Center in New York City. She specializes in medical and minimally invasive surgical management of pelvic floor disorders, including pelvic organ prolapse (cystocele, rectocele, vaginal vault prolapse, and uterine prolapse repairs), female genitourinary fistula, overactive bladder, urinary incontinence, mesh complications, refractory fecal incontinence, and urethral stricture disease (including graft reconstruction). She performs open, robotic, endoscopic, and laser surgery. She is a health services researcher with interests in the areas of urinary incontinence and refractory overactive bladder syndrome- specifically in the areas of improving health equity through access to care, reducing barriers to treatment adherence, and shared decision making in vulnerable populations (underserved, low income, frail/elderly, neurogenic lower urinary tract dysfunction). Additionally, she is an expert in OAB related-quality of life, patient outcomes, and patient satisfaction. She has authored numerous manuscripts and conducted invited lectures as well as television and radio interviews on the topic of overactive bladder.COVID-19 has presented unparalleled challenges for our most vulnerable patient populations at Stanford Medicine. As the medical director of the Stanford Multidisciplinary Pelvic Health Center, she has the unique opportunity to advance Stanford Medicine’s mission of improving health equity not in the area of pelvic floor disorders but also by training the next generation of doctors at Stanford School of Medicine.
Refractory overactive bladder in elderly and frail patient populations, detrusor underactivity, quality of life, patient outcomes, quality improvement, patient satisfaction, and shared decision making
Improving Overactive Bladder Treatment Access and Adherence
Overactive bladder (OAB) and urinary incontinence (UI) are chronic debilitating and
embarrassing conditions that affect 33 million Americans. Yet, both are underdiagnosed and
undertreated with significant financial and health-related consequences. OAB syndrome is
characterized by urinary urgency, with and without urinary incontinence, urinary frequency,
and nocturia. Evidence-based treatments are available, including behavioral therapy,
pharmacotherapy, and minimally invasive procedures. Diagnosis and treatment are also
associated with improvement in urinary symptoms and overall quality of life (QOL).3 However,
70-80% of treated patients will discontinue use of therapy in the first year due to one of
several factors (e.g., cost, tolerability, inadequate effect). In addition, only 4.7%
progress to advanced therapies suggesting undertreatment for those that need it most.
Vulnerable populations are especially at risk, as therapy utilization are lowest among older,
lower income, and/or minority groups. Poor access, insufficient patient education regarding
disease chronicity, expected outcomes, costs, and potential side effects lead to unrealistic
patient perceptions about therapy. This leads to suboptimal therapy duration, poor treatment
efficacy, adherence, and undertreatment. The study aims to evaluate a tailored
patient-centered tool to begin the treatment process.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ekene Enemchukwu, MD, MPH, 650-723-1867.
View full details